Two Sigma Advisers LP purchased a new position in Aravive Inc (NASDAQ:ARAV) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 24,596 shares of the company’s stock, valued at approximately $87,000.
Other hedge funds also recently bought and sold shares of the company. Two Sigma Investments LP purchased a new position in Aravive in the 4th quarter worth about $124,000. NF Trinity Capital Hong Kong Ltd purchased a new position in Aravive in the 4th quarter worth about $144,000. Acadian Asset Management LLC bought a new position in Aravive during the 4th quarter worth about $60,000. Geode Capital Management LLC bought a new position in Aravive during the 4th quarter worth about $105,000. Finally, Dimensional Fund Advisors LP bought a new position in Aravive during the 4th quarter worth about $484,000. 25.75% of the stock is currently owned by institutional investors.
Shares of Aravive stock opened at $5.79 on Monday. The company has a current ratio of 29.96, a quick ratio of 29.96 and a debt-to-equity ratio of 0.12. Aravive Inc has a 1 year low of $3.07 and a 1 year high of $15.30. The stock has a market cap of $65.29 million, a price-to-earnings ratio of -0.54 and a beta of 2.54.
Aravive (NASDAQ:ARAV) last issued its earnings results on Thursday, March 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.17) by ($0.03). The business had revenue of $1.37 million for the quarter. As a group, equities research analysts forecast that Aravive Inc will post -2.57 earnings per share for the current fiscal year.
Several research analysts have issued reports on the stock. ValuEngine cut shares of Aravive from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Wedbush assumed coverage on shares of Aravive in a report on Monday, April 8th. They set an “outperform” rating and a $14.00 target price on the stock.
COPYRIGHT VIOLATION WARNING: This report was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://transcriptdaily.com/2019/04/29/two-sigma-advisers-lp-purchases-new-position-in-aravive-inc-arav.html.
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Want to see what other hedge funds are holding ARAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aravive Inc (NASDAQ:ARAV).
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.